Autopsy report · NCT02969265

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

“Business reasons unrelated to product safety”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Takeda

Sponsor type

Industry

Conditions

Hypertension

Interventions

Amlodipine; TCV-116CCB; Amlodipine Placebo; TCV-116CCB Placebo

Participants

0

Sites

25

Countries

China

Trials that died the same way

• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (84% match in meaning)
• Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
  “Corporate reasons unrelated to safety and efficacy” (81% match in meaning)
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
  “Business reasons and not due to any safety concerns” (77% match in meaning)
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
  “Business decision, not related to safety” (73% match in meaning)
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.